# Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

> **NCT01174888** · PHASE1 · COMPLETED · sponsor: **Alison Walker** · enrollment: 34 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Myeloid Leukemia With Multilineage Dysplasia Following
- Myelodysplastic Syndrome
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** midostaurin
- **DRUG:** Bortezomib
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** etoposide
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT01174888
- **Lead sponsor:** Alison Walker
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-04
- **Final completion:** 2016-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-07-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01174888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01174888, "Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01174888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*